Cited by 245Extracellular vesicles in diseaseMicroRNA in disease regulationNanoparticle-Based Drug Delivery

Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p

Open access
Wei, Feng, Ma, Chengyuan, Zhou, Tong, Dong, Xuechao, Luo, Qinghua, Geng, Li, Ding, Lijuan, Zhang, Yandong +4 more·2017·Molecular Cancer

Abstract

BACKGROUND: Although gemcitabine-based chemotherapy has been established as a core multimodal therapy for non-small cell lung cancer (NSCLC) treatment, its clinical efficacy remains limited by the development of acquired resistance following tumor metastasis and relapse. In this study, we investigated how gemcitabine-resistant (GR) cells contribute to the development of NSCLC tumor malignancy via exosome-mediated transfer of microRNAs. METHODS: We first studied the mechanism of exosome internalization via PKH-67 staining and an immunofluorescence assay, then confirmed our finding by transmission electron microscopy and western blot analysis. Candidate miRNAs were identified through microarray analysis. Thereafter, RT-PCR, MTS, Transwell and soft agar assays were performed to assess the role of exosomic miR-222-3p in vitro. A 3' untranslated region reporter assay was applied to identify the target of miR-222-3p. A lung metastasis mouse model was constructed to evaluate tumor growth and metastasis in vivo. Finally, clinical samples were used for correlation analysis between exosomic miR-222-3p levels and patients' response to gemcitabine. RESULTS: A549-GR-derived exosomes were internalized by receipt cells via caveolin- and lipid raft-dependent endocytosis, which allowed the transfer of miR-222-3p. Exosomic miR-222-3p enhanced the proliferation, gemcitabine resistance, migration, invasion, and anti-anoikis of parental sensitive cells by directly targeting the promoter of SOCS3. In addition, a higher level of exosomic miR-222-3p in sera usually predicted worse prognosis in NSCLC patients. CONCLUSION: Our data demonstrate that exosomic-miR-222-3p functions as a principal regulator of gemcitabine resistance and malignant characteristics by targeting SOCS3. The exosomic miR-222-3p level in sera may be a potential prognostic biomarker for predicting gemcitabine sensitivity in NSCLC patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-017-0694-8

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In A549-P cells, endocytosis of exosomal miRNAs is mediated by caveolae- and lipid raft-dependent pathways.

    “However, another study conducted in A549-P cells showed that endocytosis of exosomal miRNAs is mediated by caveolae- and lipid raft-dependent pathways (143).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

6 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wei, F., Ma, C., Zhou, T., Dong, X., Luo, Q., Geng, L., Ding, L., Zhang, Y., Zhang, L., Li, N., Li, Y., & Liu, Y.
Affiliations
  • First Hospital of Jilin University (CN)
  • Academy of Military Medical Sciences (CN)
  • Jilin University (CN)
Corresponding author
Liu, Yan
Venue
Molecular Cancer
Published
2017-07-25
Volume
16
Issue
1
Pages
132-132
ISSN
1476-4598 (ISSN-L)
OpenAlex
W2736949652
Cited by
245
References
52
Citations by year
2026: 11 · 2025: 19 · 2024: 26 · 2023: 25 · 2022: 32 · 2021: 45 · 2020: 43 · 2019: 23 · 2018: 17 · 2017: 4
FWCI
9.72
Type
journal article
Language
en
Open access
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81301884, 81401883, 81302173)
  • Natural Science Foundation of Jilin Province (20140520036JH, 2016041052GH, 20140414027GH, 20160101053JC)
  • Jilin University (450060521279)
  • China Postdoctoral Science Foundation (2016M590264)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
exosomes, gemcitabine resistance, non-small cell lung cancer, miR-222-3p, SOCS3, caveolin-dependent endocytosis, lipid rafts, metastasis, anoikis resistance, cell proliferation and invasion, serum biomarkers, prognostic factors, chemotherapy response
MeSH terms
Gemcitabine, Animals, Carcinoma, Non-Small-Cell Lung, Cell Movement, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Gene Expression Regulation, Neoplastic, Mice, SCID, 3' Untranslated Regions, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Mice, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review